Aveo Pharmaceuticals (NASDAQ:AVEO) shares traded -2.11% down during most recent session to reach at the closing price of $2.79. The stock exchanged hands 2.61 Million shares versus average trading capacity of 5.67 Million shares, yielding a market cap of $290.91 Million. Wall Street analysts covering the stock are projecting that the stock will reach $2 within the next 52-weeks. The mean target projections are based on 1 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Aveo Pharmaceuticals (NASDAQ:AVEO) high price target of $2 and with a conservative view have low price target of $2.

PiperJaffray “Initiates Coverage on” Aveo Pharmaceuticals (NASDAQ:AVEO) in a research note issued to investors on 5/19/16 to Overweight.

Additionally on 3/30/16 FBR Capital “Initiates Coverage on” Aveo Pharmaceuticals (NASDAQ:AVEO) to Outperform and on 3/09/15 RBC Capital “Upgrades” the stock to Sector Perform at $3. Furthermore on 12/16/13 RBC Capital “Downgrades” the stock to Underperform at $2.

On the other hand the company has Relative Strength Index (RSI 14) of 65.46 along with Average True Range (ATR 14) of 0.22, Consequently Aveo Pharmaceuticals (NASDAQ:AVEO)’s weekly and monthly volatility is 9.16%, 8.07% respectively. The company’s beta value is at 1.48.

In terms of Buy, Sell or Hold recommendations, Aveo Pharmaceuticals (NASDAQ:AVEO) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Aveo Pharmaceuticals (NASDAQ:AVEO)’s minimum EPS for the current quarter is at $-0.09 and can go high up to $-0.09. The consensus mean EPS for the current quarter is at $-0.09 derived from a total of 1 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.13 earnings per share for the same quarter during last year.

Aveo Pharmaceuticals (NASDAQ:AVEO)’s revenue estimates for the current quarter are $1 Million according to 1 number of analysts, for the current quarter the company has high revenue estimates of $1 Million in contradiction of low revenue estimates of $1 Million. For the current year the company’s revenue estimates are $7.67 Million compared to low analyst estimates of $7.67 Million and high estimates of $7.67 Million according to 1 number of analysts.

Currently Aveo Pharmaceuticals (NASDAQ:AVEO)’s shares owned by insiders are 0.6%, whereas shares owned by institutional owners are 52.6%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0.16%.

Aveo Pharmaceuticals (NASDAQ:AVEO) 52-week high price stands at $3.19 and low price stands at $0.50, its price distance from 52-week high is -12.54% while its distance from 52-week low price is 459.12%. The stock hit its 52-week high on 07/10/17, and 52-week low on 03/28/17.

Aveo Pharmaceuticals (NASDAQ:AVEO)’s trailing twelve month revenues are $3.8 Million, whereas its price to sales ratio for the same period is 76.56. Its book value per share for the most recent quarter is $0.06 while its price to book ratio for the same period is 46.5, as for as the company’s cash per share for the most recent quarter is $0.32, however its price to cash per share ratio for the same period is 8.71. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.